Literature DB >> 6964227

Retinal vascular abnormalities in the hyperlipidaemias.

P M Dodson, D J Galton, A F Winder.   

Abstract

Previous studies have suggested an association between hyperlipidaemia and retinal venous and arterial occlusion. To investigate this association further, the retinal arterial vasculature was studied by fluorescein angiography in forty hyperlipidaemic subjects, and clinical examination and biochemical investigations, including lipid profile, were performed in 99 patients with retinal vein occlusion and forty patients without retinal vein occlusion as a comparison group. Retinal arterial abnormalities were found on fluorescein angiography in eight patients with combined hypercholesterolaemia and hypertriglyceridaemia (type IV and V hyperlipidaemia). However no abnormalities were found in patients with familial hypercholesterolaemia (type II). Fluorescein angiography was repeated after 6 months hypolipidaemic therapy in four of the patients with retinal arterial abnormalities. Progression of retinal vascular closure was observed in two patients with poor hyperlipidaemic control and improvement in two other patients with good hyperlipidaemic control. There was a significantly higher incidence of hyperlipidaemia (P less than 0.001) and glucose intolerance (P less than 0.05) in the retinal vein occlusion group when compared to the control group, and a higher incidence of hypertension in patients with either central or branch retinal vein occlusion than in the normal population. We conclude that retinal arterial abnormalities occur in type IV and V hyperlipidaemias and that both central and branch retinal vein occlusion are associated with similar risk factors to large vessel disease.

Entities:  

Mesh:

Year:  1981        PMID: 6964227

Source DB:  PubMed          Journal:  Trans Ophthalmol Soc U K        ISSN: 0078-5334


  9 in total

1.  Thrombus and branch retinal vein occlusion.

Authors:  E Baglivo; A Dosso; C Pournaras
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

2.  Retinal vessel responses to systemic autonomic stimulation in fellow eyes of patients with retinal vein occlusion.

Authors:  L P Lanigan; C V Clark; D W Hill
Journal:  Doc Ophthalmol       Date:  1990 Apr-Jul       Impact factor: 2.379

Review 3.  Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.

Authors:  A D Wright; P M Dodson
Journal:  Eye (Lond)       Date:  2011-03-25       Impact factor: 3.775

4.  Medical conditions underlying recurrence of retinal vein occlusion.

Authors:  P M Dodson; A J Kubicki; K G Taylor; E E Kritzinger
Journal:  Br J Ophthalmol       Date:  1985-07       Impact factor: 4.638

5.  Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients.

Authors:  R F Walters; D J Spalton
Journal:  Br J Ophthalmol       Date:  1990-01       Impact factor: 4.638

6.  Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study.

Authors:  Jamie Morton; Sophia Zoungas; Qiang Li; Anushka A Patel; John Chalmers; Mark Woodward; David S Celermajer; Joline W J Beulens; Ronald P Stolk; Paul Glasziou; Martin K C Ng
Journal:  Diabetes Care       Date:  2012-08-13       Impact factor: 19.112

7.  Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion.

Authors:  Paola Ferrazzi; Pierpaolo Di Micco; Ilaria Quaglia; Lisa Simona Rossi; Alessandro Giacco Bellatorre; Giorgio Gaspari; Lidia Luciana Rota; Corrado Lodigiani
Journal:  Thromb J       Date:  2005-09-07

8.  Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion.

Authors:  Bum-Joo Cho; So Hyun Bae; Sang Min Park; Min Chul Shin; In Won Park; Ha Kyoung Kim; Soonil Kwon
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

9.  Inflammation in the pathogenesis of microvascular complications in diabetes.

Authors:  Dung V Nguyen; Lynn C Shaw; Maria B Grant
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-21       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.